ArticleFrontiers in immunology2019
The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Comparative Evaluation of Plant-Derived Virus-like Particles as Intratumoral Immunotherapy Agents.Vaccines · 2026Article
- The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice.Nature communications · 2026Article
- Histotripsy Dose Impacts Treated Tumor Immune Infiltration and Survival Outcomes in a Murine B16F10 Melanoma Model.Cancers · 2025Article
- Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors.Pharmaceutics · 2025Article
- Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research.Biomolecules · 2024Article
- Investigating the effect of cGRP78 vaccine against different cancer cells and its role in reducing melanoma metastasis.Research in pharmaceutical sciences · 2024Article
- Nanoparticle vaccines can be designed to induce pDC support of mDCs for increased antigen display.Biomaterials science · 2023Article
- Transplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines.Oncology reviews · 2023Review
- Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies.Vaccines · 2022Review
- Combination therapies utilizing neoepitope-targeted vaccines.Cancer immunology, immunotherapy : CII · 2021Review
- Cancer Vaccines: Antigen Selection Strategy.Vaccines · 2021Review
- The Clinical Application of Neoantigens in Esophageal Cancer.Frontiers in oncology · 2021Review
- Main Strategies for the Identification of Neoantigens.Cancers · 2020Review
- Altering Antigen Charge to Control Self-Assembly and Processing of Immune Signals During Cancer Vaccination.Frontiers in immunology · 2020Article
- The Roles of Alternative Splicing in Tumor-immune Cell Interactions.Current cancer drug targets · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor neoantigens are ideal targets for cancer immunotherapy as they are recognized by host immune system as foreigners and can elicit tumor-specific immune responses. However, existing strategies utilizing RNA or long peptides for the neoantigen vaccines render limited immune responses since only 20-30% of neoantigens predicted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.